The problem of having to take multiple medications a day, testing blood sugar and other troubled diabetic patients will be solved. A "smart" drug that can "smart" hypoglycemic has entered Phase III clinical trials.
Professor Yang Wenying, Chairman of the Chinese Medical Association Diabetes Branch, and Prof. Pan Changyu, Department of Endocrinology, General Hospital of the People's Liberation Army, revealed that the new drug developed by Novo Nordisk Pharmaceuticals of Denmark was named "GLP-1 analogue liraglutide". It is a novel incretin drug, which has the effect of rapidly and efficiently lowering blood sugar, improving beta cell function, lowering body weight and blood pressure, stably controlling blood sugar levels, eliminating and reducing complications, and making patients live like healthy people.
At present, 100 medical institutions in more than 40 countries, including Beijing China-Japan Friendship Hospital and other Chinese hospitals, have carried out relevant phase III clinical trials and achieved satisfactory results. It is expected to be listed in Europe and the United States next year.
Professor Yang Wenying, who participated in the clinical laboratory research, said that the drug improved the hypoglycemic ability by changing the molecular structure. The patient can effectively reduce the sugar once a day and can effectively reduce the occurrence of hypoglycemia. When the body's blood sugar is too high, it will "prompt" the pancreas to release insulin, and when the blood sugar reaches the normal range, it will no longer emit such a signal, and the blood sugar will stay in a stable range.
Zui's new clinical data show that the drug not only delays the progression of diabetes, but also has the potential to reduce the incidence of cardiovascular complications in diabetes. This has caused widespread concern in the medical community. Some experts said at the just-concluded European Diabetes Research Conference that the drug may be a revolution in the field of diabetes treatment.
Novo Nordisk, which has more than 80 years of history, is the world leader in diabetes research and drug development. It entered China in early 1994, established Novo Nordisk (China) Pharmaceutical Co., Ltd. in Beijing and established in Beijing. *R&D center. As of the end, its staff in China has more than 1,000 people.
Professor Yang Wenying, Chairman of the Chinese Medical Association Diabetes Branch, and Prof. Pan Changyu, Department of Endocrinology, General Hospital of the People's Liberation Army, revealed that the new drug developed by Novo Nordisk Pharmaceuticals of Denmark was named "GLP-1 analogue liraglutide". It is a novel incretin drug, which has the effect of rapidly and efficiently lowering blood sugar, improving beta cell function, lowering body weight and blood pressure, stably controlling blood sugar levels, eliminating and reducing complications, and making patients live like healthy people.
At present, 100 medical institutions in more than 40 countries, including Beijing China-Japan Friendship Hospital and other Chinese hospitals, have carried out relevant phase III clinical trials and achieved satisfactory results. It is expected to be listed in Europe and the United States next year.
Professor Yang Wenying, who participated in the clinical laboratory research, said that the drug improved the hypoglycemic ability by changing the molecular structure. The patient can effectively reduce the sugar once a day and can effectively reduce the occurrence of hypoglycemia. When the body's blood sugar is too high, it will "prompt" the pancreas to release insulin, and when the blood sugar reaches the normal range, it will no longer emit such a signal, and the blood sugar will stay in a stable range.
Zui's new clinical data show that the drug not only delays the progression of diabetes, but also has the potential to reduce the incidence of cardiovascular complications in diabetes. This has caused widespread concern in the medical community. Some experts said at the just-concluded European Diabetes Research Conference that the drug may be a revolution in the field of diabetes treatment.
Novo Nordisk, which has more than 80 years of history, is the world leader in diabetes research and drug development. It entered China in early 1994, established Novo Nordisk (China) Pharmaceutical Co., Ltd. in Beijing and established in Beijing. *R&D center. As of the end, its staff in China has more than 1,000 people.
Glucose Oxidas,Enzyme Complex,Feed Grade Enzymes,Enzymes In Poultry Feed
Tangshan Finely Animal Care Co.,Ltd , https://www.faczyme.com